Preview
Unable to display preview. Download preview PDF.
Références
- 1.Blackwell KL, Burstein HJ, Storniolo AM, et al. (2010) Randomised study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124–1130PubMedCrossRefGoogle Scholar
- 2.Gianni L, Pienkowski T, Im YH, et al. (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1): 25–32PubMedCrossRefGoogle Scholar
Références
- 1.Perez-Garcia J, Cortes J (2012) A roadmap for accelerated drug approval in breast cancer? Lancet Oncol 13(9): 850–851PubMedCrossRefGoogle Scholar
- 2.Prowell TM, Pazdur R (2012) Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 366: 2438–2441PubMedCrossRefGoogle Scholar
- 3.Stilgenbauer S, Zenz T, Winkler D, et al. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27(24): 3994–4001PubMedCrossRefGoogle Scholar
- 4.Wynne C, Harvey V, Schwabe C, et al. (2012) Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol [Epub ahead of print] doi: 10.1177/0091270012436560Google Scholar
Copyright information
© Springer-Verlag France 2012